Categories: News

TE Connectivity to report second quarter financial results on April 24, 2019

SCHAFFHAUSEN, Switzerland, April 10, 2019 /PRNewswire/ — TE Connectivity Ltd. (NYSE: TEL) will report financial results for the second quarter of fiscal 2019 before trading begins on April 24, 2019. The company will hold a conference call for investors at 8:30 a.m. ET. The conference call may be accessed in the following ways:

  • At TE Connectivity’s website: investors.te.com
  • By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the United States is (800) 230-1093, and for international callers, the dial-in number is (612) 332-0107.
  • An audio replay of the conference call will be available beginning at 10:30 a.m. ET on April 24, 2019 and ending at 11:59 p.m. ET on May 1, 2019. The dial-in number for participants in the United States is (800) 475-6701. For participants outside the United States, the dial-in number is (320) 365-3844. The replay access code for all callers is 464389.

About TE Connectivity

TE Connectivity Ltd. (NYSE: TEL) is a $14 billion global technology and manufacturing leader creating a safer, sustainable, productive, and connected future. For more than 75 years, our connectivity and sensor solutions, proven in the harshest environments, have enabled advancements in transportation, industrial applications, medical technology, energy, data communications, and the home. With 80,000 employees, including more than 8,000 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/te-connectivity-to-report-second-quarter-financial-results-on-april-24-2019-300828317.html

SOURCE TE Connectivity Ltd.

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

1 hour ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

1 hour ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

1 hour ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

1 hour ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

1 hour ago